The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel (PC) or cisplatin/etoposide (PE) in stage III non-small cell lung cancer (NSCLC).
Mun Sem Liew
No relevant relationships to disclose
Joseph Sia
No relevant relationships to disclose
Samuel John Harris
No relevant relationships to disclose
Alireza Tafreshi
No relevant relationships to disclose
Maud HW Starmans
No relevant relationships to disclose
Malcolm Feigen
No relevant relationships to disclose
Paul C Boutros
No relevant relationships to disclose
Shane White
No relevant relationships to disclose
Allan Solomon Zimet
No relevant relationships to disclose
P. Lambin
No relevant relationships to disclose
Paul Mitchell
No relevant relationships to disclose
Tom John
No relevant relationships to disclose